Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,853.70 | 60.20 | -0.76% |
| CAC 40 | 7,127.50 | 1.48 | 0.02% |
| DAX 40 | 20,425.49 | 137.24 | -0.67% |
| Dow JONES (US) | 39,577.49 | 1,030.96 | -2.54% |
| FTSE 100 | 7,979.61 | 66.36 | 0.84% |
| HKSE | 20,914.69 | 232.91 | 1.13% |
| NASDAQ | 16,387.31 | 737.66 | -4.31% |
| Nikkei 225 | 33,585.58 | 1,023.42 | -2.96% |
| NZX 50 Index | 12,019.13 | 182.30 | -1.49% |
| S&P 500 | 5,276.03 | 180.87 | -3.31% |
| S&P/ASX 200 | 7,646.50 | 63.10 | -0.82% |
| SSE Composite Index | 3,238.23 | 14.59 | 0.45% |